How to Help Your Patients Save Money on Prevymis: A Provider's Guide to Savings Programs

Prevymis (letermovir) has a retail price of approximately $8,700–$9,053 or more per 30-day supply, making it one of the most expensive antiviral medications prescribed in transplant medicine. Yet most of your patients should not be paying anywhere near that amount. As the prescribing provider, your team plays a crucial role in connecting patients to the savings resources available to them. This guide covers every major program available in 2026, with actionable steps for your practice.

Why Cost Can Become a Patient Safety Issue

When patients cannot afford Prevymis, they may skip or ration doses — creating gaps in CMV prophylaxis during the period of highest immune vulnerability after transplant. Even brief interruptions in therapy are associated with CMV viremia. In HSCT patients, any level of CMV infection is associated with increased all-cause mortality through Week 24 and Week 48 post-transplant. Cost-related non-adherence is a preventable cause of poor outcomes in this population.

Program 1: Merck Savings Card for Commercially Insured Patients

The single most impactful savings program for the majority of your working-age transplant patients is Merck's copay savings card.

• Benefit: Eligible commercially insured patients pay as little as $15 per prescription, for up to 8 qualifying prescriptions per year (one month's supply per prescription)
• Eligibility: Must have commercial (private) health insurance; must be a U.S. resident; not eligible for Medicare, Medicaid, or other government programs
• How to enroll: Contact Merck Access Program at 1-855-257-3932; enrollment can be completed by your practice staff or the patient
• Clinical significance: For a 100-day HSCT course (approximately 4 refills), this program can save a patient approximately $35,000–$36,000 in copay costs, depending on their plan

Program 2: Merck Access Program for Uninsured/Underinsured Patients

For patients without commercial insurance or whose insurance denies coverage, Merck's patient assistance program can provide Prevymis at no cost to eligible patients. The program provides financial assistance to cover coinsurance, copayments, healthcare premiums, and deductibles for qualifying patients.

• Eligibility: Income-based; U.S. residents; not eligible if covered by government programs that cover the cost (except where allowed by law)
• How to initiate: Contact 1-855-257-3932. Your practice's financial counselor or social worker can facilitate enrollment.
• Turnaround time: Applications are typically reviewed within a few business days. Bridge supply may be available while applications are processed — ask the Merck access team specifically.

Program 3: Medicare Part D Coverage and the $2,000 Out-of-Pocket Cap

For Medicare patients, Prevymis is typically covered under Part D on a specialty tier with significant cost-sharing. However, the Medicare Part D out-of-pocket cap of $2,000 (effective January 1, 2025) provides meaningful financial protection for high-cost specialty drugs like Prevymis. Once a Medicare Part D enrollee reaches the $2,000 cap, their plan covers 100% of drug costs for the remainder of the calendar year.

Merck savings cards are NOT eligible for Medicare patients. For Medicare patients who struggle with Part D cost-sharing before reaching the cap, consider referring them to Extra Help (Low Income Subsidy) if they meet income criteria.

Program 4: State Pharmaceutical Assistance Programs (SPAP)

Many states offer State Pharmaceutical Assistance Programs that provide additional help with prescription drug costs for Medicare recipients who don't qualify for Extra Help. Check your state's SPAP eligibility criteria and how they may coordinate with Part D to reduce Prevymis costs for eligible patients.

Building a Financial Navigation Workflow for Prevymis Patients

A systematic approach ensures no patient falls through the cracks. Consider implementing this workflow in your transplant program:

1. Pre-discharge: Insurance verification. Confirm Prevymis is covered under the patient's plan and whether prior authorization has been submitted. Identify the patient's insurance type (commercial, Medicare, Medicaid, uninsured).
2. Pre-discharge: Savings program enrollment. Enroll commercially insured patients in the Merck savings card immediately. Initiate Merck Access Program applications for uninsured or underinsured patients.
3. Post-discharge follow-up call (Day 3-5). Confirm the patient has received their Prevymis supply and is taking it correctly. Address any barriers immediately.
4. Refill monitoring at Day 90. Ensure the next refill is ready, prior authorization hasn't expired, and savings card eligibility has not been exhausted.

Optimizing Prior Authorization to Prevent Coverage Gaps

Coverage gaps often occur not from actual insurance denials but from administrative delays: PA not submitted, documentation incomplete, or PA approval expired at refill. Streamline your PA process:

• Include a standardized PA letter in your transplant discharge documentation package that can be submitted on Day 0 of transplant
• Document CMV serostatus, transplant type, date, and intended therapy duration in every Prevymis PA request
• Set calendar reminders for PA renewal dates (most approvals are valid for 90-180 days)
• Use Merck's Access Program pharmacy liaisons to help push through denials and appeals — they have experience with payer criteria

Giving Patients a Tool to Find Prevymis at a Pharmacy

Even after insurance and savings programs are sorted, patients sometimes still struggle to find a pharmacy that stocks Prevymis. medfinder for providers is a resource you can share with your patients — it contacts pharmacies near them by phone and texts back which ones can fill the prescription. Including this information in discharge materials is a practical addition to your Prevymis access toolkit.

Bottom Line for Transplant Providers

The retail price of Prevymis is a barrier, but it is a surmountable one for most patients through manufacturer savings programs, insurance coverage, and Medicare's $2,000 out-of-pocket cap. The gap between what is available and what patients receive is often a workflow problem, not a resource problem. Proactive enrollment in the Merck savings card before discharge, systematic PA management, and patient-facing resources like medfinder can ensure your patients complete their full course of prophylaxis without cost-related interruptions. For a patient-facing guide to Prevymis savings, see: How to Save Money on Prevymis in 2026.